HANSOH PHARMAC. HD-00001 (3KY) — Working Capital to Net Assets Ratio
HANSOH PHARMAC. HD-00001 (3KY) has a Working Capital to Net Assets ratio of 88.1% as of December 2025. Working capital of €31.16 Billion (current assets of €35.56 Billion minus current liabilities of €4.39 Billion) is measured against net assets of €35.36 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
HANSOH PHARMAC. HD-00001 Working Capital to Net Assets (2021–2025)
This chart shows how HANSOH PHARMAC. HD-00001's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 88.1%, reflecting working capital of €31.16 Billion against net assets of €35.36 Billion EUR. See 3KY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for HANSOH PHARMAC. HD-00001 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for HANSOH PHARMAC. HD-00001 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see HANSOH PHARMAC. HD-00001 assets under control.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 88.1% | €31.16 Billion | €35.36 Billion | €35.56 Billion | €4.39 Billion | ▲ +1.8 pp |
| 2024 | 86.3% | €24.75 Billion | €28.68 Billion | €27.44 Billion | €2.70 Billion | ▲ +0.9 pp |
| 2023 | 85.4% | €22.02 Billion | €25.79 Billion | €28.88 Billion | €6.86 Billion | ▼ -17.1 pp |
| 2022 | 102.5% | €23.21 Billion | €22.65 Billion | €25.83 Billion | €2.62 Billion | ▲ +1.9 pp |
| 2021 | 100.6% | €20.16 Billion | €20.03 Billion | €23.18 Billion | €3.02 Billion | — |